Ultra-Sensitive Immunoassays: Beyond Biomarkers and into PK and Immunogenicity
Thursday, June 21, 2018
8AM PDT | 11AM EDT | 4PM BST | 5PM CEST
If you’ve already registered, please click here to log in to the webcast.
Ultra-sensitive immunoassays are providing key pharmacologic data to advance complex drug development pipelines across all therapeutic areas. The traditional trial and error practice of medicine is progressively eroding in favor of more precise marker-assisted diagnosis, and safer and more effective treatment of disease. Utilizing the ability to measure low femtogram/mL concentrations of cytokines, chemokines, neurologic markers in blood, and other biomolecules (including nucleic acids by hybridization) can provide differentiating information relevant to advancing drug discovery and development pipelines. In addition to biomarker analysis, researchers now utilize SIMOA (Single Molecule Array) for PK and immunogenicity applications to solve complex issues such as drug tolerance and neutralizing antibody characterization for immunogenicity, as well as assessment of low frequency biomolecules for PK (including blood:brain barrier penetration, inhaled biomolecules, ocular fluids, transdermals, etc). Given the rapid uptake of new programs in Immuno-Oncology (including Liquid Biopsy), this presents many opportunities to further enhance the understanding of this rapidly advancing field of study that will lead to new predictive and companion diagnostics.
During this webcast you will learn:
- Latest advances in biomarker testing and applications
- How to measure biomolecules approximately 1000x more sensitively than prior generations of immunoassay technology
- How to solve drug tolerance and characterization issues for immunogenicity
This webcast has been produced on behalf of the sponsor who retains sole responsibility for content. About this content